TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29179770

Group type: EXPERIMENTAL
Intervention: Fistula repair
Number of subjects: 148
Study: 29180344

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Memory compensation training
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Support groups
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Wellness education
Number of subjects: 300

Group type: COMPARATOR
Intervention: Other four interventions withheld
Number of subjects: 300
Study: 29180345

Group type: EXPERIMENTAL
Intervention: In-person MBI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eHealth MBI
Number of subjects: 0
Study: 29180545

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-led medication therapy management (MTM) service enhanced by a clinical decision support system (CDSS) and pharmacogenomics (PGx) testing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-led MTM Plus service
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacogenomics (PGx) testing
Number of subjects: 0
Study: 29180633

Group type: EXPERIMENTAL
Intervention: Adaptive therapy using patient-specific tumor dynamics
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard abiraterone dosing
Number of subjects: 11
Study: 29181002

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Propofol and Isoflurane
Number of subjects: 0
Study: 29181489

Group type: EXPERIMENTAL
Intervention: CNP520 (a beta-site-amyloid precursor protein-cleaving enzyme inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29181490

Group type: EXPERIMENTAL
Intervention: Lanabecestat (AZD3293/LY3314814)
Number of subjects: 0
Study: 29181491

Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037), a human monoclonal antibody targeting aggregated forms of Aβ, administered in an ongoing phase Ib trial (PRIME).
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037) in patients with prodromal or mild AD.
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Aducanumab (BIIB037) in ApoE ε4 carriers.
Number of subjects: 196
Study: 29181702

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: UK-PBC risk score
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Globe score
Number of subjects: 474
Study: 29181829

Group type: EXPERIMENTAL
Intervention: Long-term endurance training (150 min/week moderate or 75 min/week intense exercise)
Number of subjects: 36
Study: 29182496

Group type: EXPERIMENTAL
Intervention: BGJ398 125 mg once daily for 21 days, then 7 days off (28-day cycles)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: BGJ398
Number of subjects: 61
Study: 29182729

Group type: EXPERIMENTAL
Intervention: Opioids (morphine equivalent dose given 24 hours prior to extubation)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inspiratory airway obstruction (MEF50/MIF50 ≥ 1) assessed by bedside spirometry
Number of subjects: 56
Study: 29182737

Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 475

Group type: COMPARATOR
Intervention: Women without PCOS (comparison group)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Self-efficacy of dietary behaviors
Number of subjects: 475
Study: 29182949

Group type: EXPERIMENTAL
Intervention: Liquified petroleum gas (LPG) cookstove intervention
Number of subjects: 0
Study: 29183318

Group type: EXPERIMENTAL
Intervention: Clinical pathways (CPWs) for COPD implemented in experimental groups
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control groups (no CPWs implemented)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Healthcare utilization measures (hospital admission rates, hospital length of stay, GP visits)
Number of subjects: 4
Study: 29183337

Group type: EXPERIMENTAL
Intervention: Dynamic respiration-synchronized couch motion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Static segments
Number of subjects: 100
Study: 29183360

Group type: EXPERIMENTAL
Intervention: Rounded percentiles
Number of subjects: 5836

Group type: COMPARATOR
Intervention: Z-scores
Number of subjects: 5836
Study: 29183379

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait (RAG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Free gait without robot assistance (FG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Robot-assisted gait with zero torque (RAG-Z)
Number of subjects: 30
Study: 29183868

Group type: EXPERIMENTAL
Intervention: Home-based HIV testing with remote video-based counseling
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group receiving one HIV self-testing kit and reporting results via website
Number of subjects: 200
Study: 29183928

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion of the liver (NMP-L) following a period of static cold storage.
Number of subjects: 0
Study: 29183960

Group type: EXPERIMENTAL
Intervention: Radium-223 55 kBq/kg intravenously every 4 weeks × 6
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 184
Study: 29184049

Group type: EXPERIMENTAL
Intervention: Diaphragmatic electrical activity (EA) measurement before extubation
Number of subjects: 21
Study: 29184532

Group type: EXPERIMENTAL
Intervention: Patients with new distant lesions (n=16, 14%)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Patients with new local lesions (n=99, 86%)
Number of subjects: 115
Study: 29184537

Group type: EXPERIMENTAL
Intervention: VSL#3 probiotics
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 80
Study: 29184781

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation with coordinated combined chemotherapy
Number of subjects: 0
Study: 29185021

Group type: EXPERIMENTAL
Intervention: Surgical training and standardised management guidelines (Group C)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Surgical training and experience (Group A)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Plastic surgeons (Group B)
Number of subjects: 209
Study: 29185557

Group type: EXPERIMENTAL
Intervention: Low-dose IV alteplase (0.6 mg/kg)
Number of subjects: 3139

Group type: COMPARATOR
Intervention: Standard-dose IV alteplase (0.9 mg/kg)
Number of subjects: 3139

Group type: EXPERIMENTAL
Intervention: Seizures
Number of subjects: 3139
Study: 29185786

Group type: EXPERIMENTAL
Intervention: Low exposure desvenlafaxine (20, 30, or 35 mg/day based on baseline weight)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: High exposure desvenlafaxine (25, 35, or 50 mg/day based on baseline weight)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 29186375

Group type: EXPERIMENTAL
Intervention: Minimally invasive mitral valve surgery (MICS)
Number of subjects: 256
Study: 29186458

Group type: EXPERIMENTAL
Intervention: 4-days-a-week antiretroviral regimen
Number of subjects: 100
Study: 29187226

Group type: EXPERIMENTAL
Intervention: Educational video on informed consent process
Number of subjects: 30
Study: 29187343

Group type: EXPERIMENTAL
Intervention: eHealth application for self-reported SRIIPS
Number of subjects: 28
Study: 29187390

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 1557

Group type: EXPERIMENTAL
Intervention: Central sleep apnea (CSA)
Number of subjects: 1557

Group type: EXPERIMENTAL
Intervention: Coexisting obstructive and central sleep apnea (OSA-CSA)
Number of subjects: 1557

Group type: EXPERIMENTAL
Intervention: Periodic breathing (Cheyne-Stokes respiration)
Number of subjects: 1557

Group type: EXPERIMENTAL
Intervention: Risk factors for CSA vs OSA
Number of subjects: 1557
Study: 29187850

Group type: EXPERIMENTAL
Intervention: Roux-en-Y bariatric surgery
Number of subjects: 37
Study: 29188387

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg b.i.d.
Number of subjects: 517

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg q.d.
Number of subjects: 517
Study: 29188408

Group type: EXPERIMENTAL
Intervention: Demcizumab (5 mg/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Demcizumab (2.5, 5.0, and 7.5 mg/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Truncated regimen of demcizumab
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Demcizumab (5 mg/kg q3-weekly ×4)
Number of subjects: 46
Study: 29188469

Group type: EXPERIMENTAL
Intervention: Merestinib (type II MET kinase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emibetuzumab (bivalent anti-MET antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Merestinib and Emibetuzumab
Number of subjects: 0
Study: 29188734

Group type: EXPERIMENTAL
Intervention: Current and lifetime DSM-IV diagnoses of axis-I (psychiatric disorders) and axis-II (personality disorders) assessed using structured clinical interviews (SCID-I and -II)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Self-rated psychiatric symptoms evaluated via the Symptom Check List-90 (SCL-90), Beck Depression Inventory, and Dissociative Experiences Scale (DES)
Number of subjects: 83
Study: 29189665

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) of busulfan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Initial busulfan dose based on age/weight
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Quality control (QC) measurements
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Storage at -80°C
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cross-validation of analytical methods
Number of subjects: 18
Study: 29189677

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir-based ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: nevirapine-based ART
Number of subjects: 0
Study: 29189950

Group type: EXPERIMENTAL
Intervention: Oral care program using a foam stick (Period 1)
Number of subjects: 2030

Group type: EXPERIMENTAL
Intervention: Oral care program using a foam stick and tooth brushing with aspiration (Period 2)
Number of subjects: 2030

Group type: EXPERIMENTAL
Intervention: Cost assessment of the oral care program
Number of subjects: 2030
Study: 29190340

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (nondiabetic participants)
Number of subjects: 11
Study: 29190707

Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic boost (18 Gy, 3x6Gy) after conventional radiotherapy (46 Gy by IMRT or 3D conformal radiotherapy)
Number of subjects: 76
Study: 29190925

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus S-1
Number of subjects: 0
Study: 29191334

Group type: EXPERIMENTAL
Intervention: Treatment for secondary mitral regurgitation
Number of subjects: 0
Study: 29191581

Group type: EXPERIMENTAL
Intervention: HLA-A2 positive patients
Number of subjects: 545

Group type: COMPARATOR
Intervention: HLA-A2 negative patients
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: HLA-A2 status
Number of subjects: 545
Study: 29191595

Group type: EXPERIMENTAL
Intervention: Intermittent pulsatile dacomitinib in Cohort A (EGFR T790M)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intermittent pulsatile dacomitinib in Cohort B (unselected patients)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Adverse events from intermittent pulsatile dacomitinib
Number of subjects: 38
Study: 29191814

Group type: EXPERIMENTAL
Intervention: Anticipated partner notification (PN) practices
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Actual partner notification (PN) outcomes
Number of subjects: 150
Study: 29191852

Group type: EXPERIMENTAL
Intervention: All patients in the CREST trial
Number of subjects: 2502
Study: 29191916

Group type: EXPERIMENTAL
Intervention: Duvelisib 8 to 100 mg twice daily (MTD determined as 75 mg twice daily)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Duvelisib 25 or 75 mg twice daily continuously
Number of subjects: 210
Study: 29191954

Group type: EXPERIMENTAL
Intervention: Mandibular movement test
Number of subjects: 0
Study: 29191961

Group type: EXPERIMENTAL
Intervention: FCRx
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Immunosuppression (SIS)
Number of subjects: 0
Study: 29192743

Group type: EXPERIMENTAL
Intervention: High adrenomedullin levels
Number of subjects: 440

Group type: COMPARATOR
Intervention: Low adrenomedullin levels
Number of subjects: 440
Study: 29193118

Group type: EXPERIMENTAL
Intervention: Allogeneic red blood cell transfusion
Number of subjects: 0
Study: 29193542

Group type: EXPERIMENTAL
Intervention: quantitative fibrous collagen parameters (q-FP)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Ishak fibrosis staging
Number of subjects: 301
Study: 29193547

Group type: EXPERIMENTAL
Intervention: telbivudine 600 mg/day from gestation 28-32 weeks to 3-4 weeks postpartum
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control (no antiviral agent)
Number of subjects: 328
Study: 29193741

Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup (HFCS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Whole-wheat foods
Number of subjects: 17
Study: 29193757

Group type: EXPERIMENTAL
Intervention: C + vitamin E + selenium (C + A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: C + sunflower oil (C + O)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control diet (C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: C + sunflower oil + vitamin E + selenium (A + O)
Number of subjects: 60
Study: 29194206

Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry (SLP) temporal-inferior RNFL
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Spectral-domain Optical Coherence Tomography (SD-OCT) temporal-inferior RNFL
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nerve fiber indicator from SLP
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: SD-OCT mean
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Both GDx-VCC and SD-OCT
Number of subjects: 207

Group type: COMPARATOR
Intervention: PPV comparison between SLP and SD-OCT
Number of subjects: 207

Group type: COMPARATOR
Intervention: NPV comparison between SLP and SD-OCT
Number of subjects: 207
Study: 29194623

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation plus perioperative SOX chemotherapy
Number of subjects: 40
Study: 29194665

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FIBRYGA, Octapharma AG)
Number of subjects: 13
Study: 29195494

Group type: EXPERIMENTAL
Intervention: Financial incentives-based workplace wellness program
Number of subjects: 292
Study: 29195593

Group type: EXPERIMENTAL
Intervention: Computerized brief intervention (BI)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: In-person brief intervention (BI)
Number of subjects: 359
Study: 29195764

Group type: EXPERIMENTAL
Intervention: Computer decision support system (CDSS) for suicidality screening
Number of subjects: 2134

Group type: EXPERIMENTAL
Intervention: CDSS for suicidality screening
Number of subjects: 2134
Study: 29196279

Group type: EXPERIMENTAL
Intervention: mHealth-based self-management intervention
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: paper-based self-management intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: contact-control intervention
Number of subjects: 46
Study: 29196412

Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine IV at 40 µg/kg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine IV at 5-60 µg/kg or 20 µg/kg on days 1 and 4 of 21-day cycles
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine IV
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine IV in patients achieving CR or CRi
Number of subjects: 131
Study: 29196482

Group type: EXPERIMENTAL
Intervention: Decreased exercise level between 15 and 20 weeks' gestation
Number of subjects: 1200

Group type: COMPARATOR
Intervention: No change in exercise level up to 20 weeks' gestation
Number of subjects: 1200
Study: 29196542

Group type: EXPERIMENTAL
Intervention: cMyC concentration in patients with aortic stenosis
Number of subjects: 161
Study: 29197216

Group type: EXPERIMENTAL
Intervention: C9+ individuals
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: C9+ individuals (younger than 40 years)
Number of subjects: 80

Group type: COMPARATOR
Intervention: C9- individuals
Number of subjects: 80
Study: 29197547

Group type: EXPERIMENTAL
Intervention: 270 μg of aerosolized albuterol sulfate administered with a metered dose inhaler with space chamber
Number of subjects: 25
Study: 29197984

Group type: EXPERIMENTAL
Intervention: Dependent marijuana users
Number of subjects: 37

Group type: COMPARATOR
Intervention: Matched non-using controls
Number of subjects: 37
Study: 29198079

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin and naproxen sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (low-dose aspirin only)
Number of subjects: 0
Study: 29198186

Group type: EXPERIMENTAL
Intervention: Opioid risk screening tool implementation at trauma centers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized measures of socio-demographics, substance use history, opioid misuse risk, mental health, medical history, and injury and pain severity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forward stepwise regression analysis
Number of subjects: 0
Study: 29198545

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HR-QoL) questionnaire
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Severity score for health conditions
Number of subjects: 656
Study: 29198845

Group type: EXPERIMENTAL
Intervention: Gardening both during childhood and recently
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Gardening frequency (monthly or weekly)
Number of subjects: 1121
Study: 29199321

Group type: EXPERIMENTAL
Intervention: ACC-001 3 µg + QS-21
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ACC-001 10 µg + QS-21
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 29199322

Group type: EXPERIMENTAL
Intervention: AZD3293
Number of subjects: 184

Group type: COMPARATOR
Intervention: AZD3839
Number of subjects: 184

Group type: COMPARATOR
Intervention: AZ1340
Number of subjects: 184
Study: 29200184

Group type: EXPERIMENTAL
Intervention: HIV-infected children
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy control children
Number of subjects: 51
Study: 29200971

Group type: EXPERIMENTAL
Intervention: ADAMTS13 and vWF/ADAMTS13 ratio
Number of subjects: 258

Group type: COMPARATOR
Intervention: Aspirin treatment
Number of subjects: 258
Study: 29201153

Group type: EXPERIMENTAL
Intervention: Poor glycaemic control (HbA1c levels not specified)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Exercise training (details not specified)
Number of subjects: 64
Study: 29201377

Group type: EXPERIMENTAL
Intervention: Wearable devices (wrist-worn personal fitness tracker)
Number of subjects: 50
Study: 29201388

Group type: EXPERIMENTAL
Intervention: PtDA intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study: 29201402

Group type: EXPERIMENTAL
Intervention: Correct implant knowledge
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Intent to use implant
Number of subjects: 634
Study: 29201430

Group type: EXPERIMENTAL
Intervention: On-campus same-day contraceptive clinic for long-acting reversible contraception (LARC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up survey
Number of subjects: 0
Study: 29201490

Group type: EXPERIMENTAL
Intervention: Radical EBRT
Number of subjects: 16
Study: 29201994

Group type: EXPERIMENTAL
Intervention: Speed of processing cognitive training
Number of subjects: 2802

Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 2802
Study: 29202623

Group type: EXPERIMENTAL
Intervention: ANX005, administered intravenously once weekly for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-in-human starting dose of ANX005
Number of subjects: 0
Study: 29202720

Group type: EXPERIMENTAL
Intervention: High-precision radiotherapy with 5×5 Gy in 1 week
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional radiotherapy with 5×4 Gy in 1 week
Number of subjects: 44
Study: 29202727

Group type: EXPERIMENTAL
Intervention: 6-day Holter monitoring
Number of subjects: 1511
Study: 29202744

Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase (MMP)-generated fragments of collagen type I (C1M) and type VI (C6M) assessed in month six serum samples.
Number of subjects: 1000
Study: 29202780

Group type: COMPARATOR
Intervention: TGF-β isoforms (TGF-β1, TGF-β2, TGF-β3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TGF-β3
Number of subjects: 120
Study: 29202839

Group type: EXPERIMENTAL
Intervention: Cord tissue
Number of subjects: 295

Group type: COMPARATOR
Intervention: Cord blood
Number of subjects: 295
Study: 29202957

Group type: EXPERIMENTAL
Intervention: Parental recommendation to bank sperm
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Perceived self-efficacy to facilitate banking
Number of subjects: 122
Study: 29203493

Group type: EXPERIMENTAL
Intervention: Trough concentrations of >15 mg/liter
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: AUC-guided dosing with BestDose Bayesian software
Number of subjects: 252
Study: 29203498

Group type: EXPERIMENTAL
Intervention: Systematic screening using serial measurements of high-sensitivity cardiac troponin T
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Patients without PMI
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: Patients with PMI not fulfilling additional criteria for spontaneous acute myocardial infarction
Number of subjects: 2018
Study: 29203585

Group type: EXPERIMENTAL
Intervention: selinexor (3-60 mg/m2)
Number of subjects: 25
Study: 29203590

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human IL15 (rhIL15)
Number of subjects: 0
Study: 29204372

Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) breakfast and afternoon snack
Number of subjects: 11

Group type: COMPARATOR
Intervention: High glycemic index (GI) intervention
Number of subjects: 11
Study: 29204958

Group type: EXPERIMENTAL
Intervention: Ingenol disoxate gel
Number of subjects: 58
Study: 29205492

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus eluting stents (PF-SES)
Number of subjects: 2672